Warning: fopen(/home/virtual/enm-kes/journal/upload/ip_log/ip_log_2025-05.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 100 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 101
1Department of Clinical Laboratory, Gansu Provincial Hospital, Lanzhou, China
2Physical Examination Center, Gansu Provincial Hospital, Lanzhou, China
3Department of Radiology, Gansu Provincial Hospital, Lanzhou, China
Copyright © 2023 Korean Endocrine Society
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was reported.
AUTHOR CONTRIBUTIONS
Conception or design: Y.L., L.H.W., S.Z. Acquisition, analysis, or interpretation of data: W.X.Z., D.H.L., Y.J.Z., F.N.S. Drafting the work or revising: Y.L., L.H.W., S.Z. Final approval of the manuscript: Y.L., W.X.Z., D.H.L., L.H.W., Y.J.Z., F.N.S., S.Z.
Nationality | TSH, mIU/L | Equipment | Method | Reference |
---|---|---|---|---|
China (present study) | 0.70–4.93 | Chemiluminescence immunometric assay | Direct method | |
Korea | 0.62–6.84 | Electro-chemiluminescence immunoassays | Direct method | [32] |
Japan | 0.44–4.93 | Electro-chemiluminescence immunoassays | Direct method | [33] |
India | 1.134–7.280 | Electro-chemiluminescence immunoassays | Direct method | [34] |
Turkey | 0.41–4.37 | Electro-chemiluminescence immunoassays | Indirect method | [35] |
Australia | 0.43–3.28 | Abbott Architect ci16200 | Direct method | [36] |
USA | 0.33–5.8 (total) | Chemiluminescence immunometric assay | Direct method | [37] |
0.29–6.47 (White) | ||||
0.37–3.9 (Black) | ||||
0.38–5.72 (Mexican Americans) | ||||
Brazil | 0.56–4.45 | Electro-chemiluminescence immunoassays | Direct method | [38] |
German | 0.57–3.32 | Chemiluminescence immunometric assay | Direct method | [39] |
France | 0.64–3.24 | Chemiluminescence immunometric assay/Electro-chemiluminescence immunoassays | Direct method | [40] |
England | 0.3–4.5 | Electro-chemiluminescence immunoassays | Direct method | [41] |
Italy | 0.362–5.280 | Enzymatic chemiluminescence immunoassays | Direct method | [42] |
Characteristic | Total | Men | Women | Statistics | P value |
---|---|---|---|---|---|
Number | 3,123 | 1,680 | 1,443 | ||
Age, yr | 48 (40–54) | 53 (47–66) | 55 (48–67) | –1.25 | 0.21 |
SBP, mm Hg | 125 (114–136) | 139 (128–167) | 134 (121–162) | –5.94 | 0.00 |
DBP, mm Hg | 79 (70–87) | 89 (80–110) | 76 (83–102) | –6.43 | 0.00 |
BMI, kg/m2 | 24.22 (21.99–26.37) | 27.10 (25.10–31.89) | 25.15 (22.94–30.74) | 8.19 | 0.00 |
Abnormal ATPO or ATG | 806 (25.81) | 491 (15.72) | 315 (10.09) | 94.61 | 0.00 |
History of thyroid disease | 81 (2.59) | 23 (0.74) | 58 (1.86) | 19.54 | 0.00 |
Family history of thyroid disease | 19 (0.61) | 17 (0.54) | 2 (0.06) | 9.79 | 0.00 |
Thyroid ultrasonography | 1,205 (38.58) | 642 (20.56) | 563 (18.03) | 0.21 | 0.66 |
T2DM | 100 (3.20) | 68 (2.18) | 32 (1.02) | 8.39 | 0.00 |
EH | 820 (26.26) | 493 (15.79) | 327 (10.21) | 17.91 | 0.00 |
Pregnancy | 8 (0.25) | - | 8 (0.25) | - | - |
Smoking | 203 (6.50) | 185 (5.92) | 18 (0.58) | 122.71 | 0.00 |
Hepatitis or other chronic diseases | 35 (1.12) | 25 (0.80) | 10 (0.32) | 4.23 | 0.04 |
Correlation factor | TSH (Spearman, P) | TT3 (Pearson, P) | TT4 (Pearson, P) | ATG (Spearman, P) | ATPO (Spearman, P) |
---|---|---|---|---|---|
Sex | 0.23, 0.00 | –0.20, 0.00 | 0.05, 0.09 | 0.10, 0.00 | 0.09, 0.00 |
Age | 0.11, 0.00 | –0.00, 0.95 | 0.08, 0.01 | –0.01, 0.66 | 0.18, 0.00 |
Variable | Sex | Age, yr-old | Number | Mean±SD or median (IQR) | Range (2.5–97.5) | RIs after age combination | RIs for the total population | Manufacturer instructions |
---|---|---|---|---|---|---|---|---|
TSH, mIU/L | Male | 20–30 | 92 | 1.65 (1.22–2.20) | 0.83–4.26 | 0.67–4.62 | 0.70–4.93 | 0.35–4.94 |
30–40 | 175 | 1.72 (1.24–2.29) | 0.69–3.98 | |||||
40–50 | 244 | 1.79 (1.28–2.54) | 0.63–4.34 | |||||
50–70 | 153 | 1.90(1.35–2.73) | 0.64–5.48 | |||||
Female | 0–30 | 79 | 2.05 (1.46–2.75) | 0.65–4.66 | 0.72–5.15 | |||
30–40 | 90 | 1.88 (1.41–2.77) | 0.65–4.66 | |||||
40–50 | 168 | 2.31 (1.68–3.04) | 0.71–5.34 | |||||
50–70 | 108 | 2.49 (1.90–3.49) | 0.54–5.17 | |||||
TT3, nmol/L | Male | 20–30 | 92 | 1.54±0.25 | 0.98–1.97 | 1.07–1.91 | 1.05–1.88 | 0.98–2.33 |
30–40 | 175 | 1.46±0.21 | 1.01–1.87 | |||||
40–50 | 244 | 1.50±0.23 | 1.04–1.92 | |||||
50–70 | 153 | 1.49±0.19 | 1.11–1.86 | |||||
Female | 0–30 | 93 | 1.45±0.18 | 1.08–1.77 | 1.05–1.78 | |||
30–40 | 175 | 1.39±0.20 | 1.01–1.75 | |||||
40–50 | 244 | 1.40±0.20 | 1.05–1.78 | |||||
50–90 | 157 | 1.43±0.23 | 0.97–1.94 | |||||
TT4, pmol/L | Male | 0–30 | 92 | 99.75±13.01 | 73.38–124.50 | 70.52–125.08 | 70.56–125.51 | 62.68–150.84 |
30–40 | 90 | 95.28±14.24 | 67.97–126.83 | |||||
40–50 | 168 | 96.10±14.72 | 70.15–125.31 | |||||
50–70 | 153 | 99.80±13.64 | 70.62–124.53 | |||||
Female | 0–30 | 72 | 97.31±13.52 | 75.30–127.01 | 70.26–126.00 | |||
30–40 | 93 | 98.05±15.87 | 64.77–128.33 | |||||
40–50 | 175 | 97.52±14.01 | 70.47–125.77 | |||||
50–90 | 244 | 101.26±13.45 | 68.89–124.37 | |||||
ATG, IU/mL | Male | 0–30 | 92 | 0.94 (0.70–1.30) | 0.31–3.15 | <2.90 | <3.12 | <4.11 |
30–40 | 175 | 0.90 (0.70–1.36) | 0.38–2.86 | |||||
40–50 | 244 | 0.86 (0.68–1.20) | 0.34–2.94 | |||||
50–70 | 153 | 1.00 (0.76–1.40) | 0.11–3.15 | |||||
Female | 0–30 | 79 | 1.16 (0.80–1.68) | 0.42–3.55 | <3.73 | |||
30–40 | 90 | 0.88 (0.70–1.30) | 0.38–3.73 | |||||
40–50 | 168 | 1.05 (0.78–1.55) | 0.42–3.10 | |||||
50–90 | 108 | 0.97 (0.71–1.59) | 0.23–3.44 | |||||
ATPO, IU/mL | ||||||||
Male | 0–30 | 92 | 0.46 (0.20–1.71) | 0.00–4.90 | <4.60 | <4.80 | <5.61 | |
30–40 | 175 | 0.50 (0.20–1.69) | 0.00–4.89 | |||||
40–50 | 244 | 0.50 (0.20–1.83) | 0.00–4.20 | |||||
50–70 | 153 | 1.37 (0.44–2.94) | 0.00–5.21 | |||||
Female | 0–30 | 79 | 0.84 (0.33–2.08) | 0.00–4.75 | <5.26 | |||
30–40 | 90 | 1.20 (0.48–2.48) | 0.00–4.31 | |||||
40–50 | 168 | 1.40 (0.50–2.90) | 0.00–4.98 | |||||
50–90 | 108 | 1.26 (0.42–3.00) | 0.00–5.26 |
Nationality | TSH, mIU/L | Equipment | Method | Reference |
---|---|---|---|---|
China (present study) | 0.70–4.93 | Chemiluminescence immunometric assay | Direct method | |
Korea | 0.62–6.84 | Electro-chemiluminescence immunoassays | Direct method | [32] |
Japan | 0.44–4.93 | Electro-chemiluminescence immunoassays | Direct method | [33] |
India | 1.134–7.280 | Electro-chemiluminescence immunoassays | Direct method | [34] |
Turkey | 0.41–4.37 | Electro-chemiluminescence immunoassays | Indirect method | [35] |
Australia | 0.43–3.28 | Abbott Architect ci16200 | Direct method | [36] |
USA | 0.33–5.8 (total) | Chemiluminescence immunometric assay | Direct method | [37] |
0.29–6.47 (White) | ||||
0.37–3.9 (Black) | ||||
0.38–5.72 (Mexican Americans) | ||||
Brazil | 0.56–4.45 | Electro-chemiluminescence immunoassays | Direct method | [38] |
German | 0.57–3.32 | Chemiluminescence immunometric assay | Direct method | [39] |
France | 0.64–3.24 | Chemiluminescence immunometric assay/Electro-chemiluminescence immunoassays | Direct method | [40] |
England | 0.3–4.5 | Electro-chemiluminescence immunoassays | Direct method | [41] |
Italy | 0.362–5.280 | Enzymatic chemiluminescence immunoassays | Direct method | [42] |
Values are expressed as median (interquartile range) or number (%). SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; ATPO, antithyroid peroxidase; ATG, antithyroglobulin; T2DM, type 2 diabetes mellitus; EH, essential hypertension.
Pearson or Spearman rank correlation coefficients ( TSH, thyroid-stimulating hormone; TT3, total triiodothyronine; TT4, total thyroxine; ATG, antithyroglobulin; ATPO, antithyroid peroxidase.
SD, standard deviation; IQR, interquartile range; RI, reference interval; TSH, thyroid-stimulating hormone; TT3, total triiodothyronine; TT4, total thyroxine; ATG, antithyroglobulin; ATPO, antithyroid peroxidase.
TSH, thyroid-stimulating hormone.